Hypoxemia in the ED. Joseph Shiber, MD, FACP, FACEP, FCCM Director Advanced Lung/ECMO Service Professor of Emergency Medicine, Neurology, and Surgery

Transcription

1 Hypoxemia in the ED Joseph Shiber, MD, FACP, FACEP, FCCM Director Advanced Lung/ECMO Service Professor of Emergency Medicine, Neurology, and Surgery 19 y/o woman SOB s/p bicyclist struck Helmeted, no LOC and GCS 15 Open Femur Fx and closed Humerus Fx Hr 100, BP 120/75, RR 22, Sat 89% on RA; 93% on NRB Initial CXR Normal FAST (-) but repeat Lung increased B Lines More dyspneic unable to talk, appears distressed Plan for Intubation: Pre-oxygenation? RSI vs DSI? Sux vs Roc? 1

2 Now what? Sat 85% on 100% FiO2 Increase PEEP? Bilateral Chest Tubes? Ask for Bronch? Disconnect and Bag Pt? Turn MV up to 11? Outline O2 and Lung Physiology ARDS Lung Protective Ventilation: ARDSNet Prone Positioning Oscillator (HFOV) Airway Pressure Release Ventilation (APRV) Adjuncts: ino, Flolan, Paralytics, Steroids Extracorporeal Therapies (ECMO, ECLA, ECCO2R) Permissive Hypoxemia 2

3 O2 Delivery DO2 = CO x Hgb x Sat x PO2 Tissue extraction only 25% at rest but can increase to 60% O2 delivery increases by 2-4 fold by increased CO (HR, SV) and Min Ventilation Re-Distribute blood/o2 To brain, heart, muscle while Away skin, gonads, GI Brain least tolerant of hypoxia but better tolerates IF good cerebral perfusion Usual Targets: CI 2L, Hgb 7g, Sat 88%, PO2 55 = adequate tissue metabolism Causes of Hypoxemia V/Q Mismatch: pneumonia, CHF, ARDS, pulm contusion, PE Shunt: intra-cardiac R to L (PFO) or intra-pulmonary Hypoventilation: drugs, weakness, airway [A-a Gradient will be NORMAL] Diffusion ABNL: interstitial fibrosis Low PO2: high altitude, scuba, enclosed fire, simple asphyxiants Low Venous Sat: profound shock or critical anemia [adds to other causes] 3

4 Lung Physiology Work of Breathing: Resistance to Airflow + Compliance of Lung/Chest Wall WOB increased: metabolic rate (fever, sepsis, SZ), bronchial DO, over-resuscitation Lung Injury: Stress (transpulmonary pressure) and Strain (change in volume) O2 toxicity: >80% avoid if possible while <40% considered Safe Restrictive Volume ~ Dry Sick Lungs>Wet Sick Lungs (but keep out of shock) ARDS 1st described in 1967 by Ashbaugh series12 patients Affects 200,000 patients annually Life threatening condition characterized by Hypoxemia Reduced lung compliance Alveolar capillary damage leading to Inflammation Permeability Edema Necrosis Fibrosis 4

5 ARDS Definition Etiologies Treatment of underlying condition #1 priority 5

6 Lung Protective Ventilation: ARDSnet Mortality reduction 8% using 6 vs 12 cc/kg IBW, PLP<30 vs 50 Protects non-ventilated lung Why is it a problem to breath at Normal volumes 8-10 cc/kg? Baby-Lung concept of ARDS by Gattinoni Not stiff simply small BUT may have recruitable volume Chest CT to evaluate and then PEEP/MAP trial. POCUS easy, repeatable Posterior-Basilar: CXR underestimates 6

7 Using ARDSnet PCO2 clearance with low TV requires high RR May need deep sedation or NMBA to tolerate ARDSnet Spontaneous breathing decreases lung inflammation VAP, diaphragm paralysis, atelectasis = smaller lung Available lung not able to meet gas exchange needs Oscillator: HFOV Constant high MAP, insignificant TV, RR Improves recruitment and lung inflammation Reduces volutrauma & atelectrauma but not barotrauma Requires deep sedation and paralysis: no breathing Reduced pulm toilet and humidification = VAP, severe plugging Two trials (-) for early use so only consider rescue Tx 7

8 Prone Positioning Improves V/Q matching, secretion clearance and lymphatic drainage Assists recruitment of posterior-basilar segments Decreased mortality but requires >12-16 hrs daily Very work intensive if not specialty bed Requires expertise to avoid complications Consider other positions or avoid need to prone Airway Pressure Release Ventilation Three decades considered rescue mode for ARDS Improves V/Q, P/F, Peak Pressure, CO, gut/renal perfusion Spontaneous breathing: comfort, diaphragm strength Animal models: prevented pathological lung changes Reduced endothelial injury, IL1,6,8 levels, surfactant loss Reduced micro-strain: blocks process leading to VILI 8

9 APRV: How it Works CPAP with Brief Releases Recruits but Stabilizes Lung Requires Spontaneous Breathing Prolonged Time Hold Open-Lung Model of Protective Ventilation Dynamic settings adjusted to current lung status APRV: Benefits Very low rate ARDS (1.3%) in high-risk trauma cohort Used as Primary mode of MV to prevent ARDS/VILI Low mortality (3.9%) vs. similar groups (14.1%) Decreased Opiate and Sedative requirement in TBI Actually had lower pain scores and less need for BAL Decreased time on MV, ICU LOS, and mort trend w/ards 9

10 Adjuncts: selective pulmonary vasodilators ino: improves oxygenation but not survival May increase renal dysfunction, methemoglobin Epoprostenol (PGI2) inhaled: improves oxygenation Unclear if improves outcomes Temporizing measures while implementing other Tx Paralytics Early trial but only briefly (<48 hrs) Gain benefits but avoid complications: severe weakness, PTSD Reduce MV dysynchrony: tolerate ARDSnet regimen Reduce O2 consumption: take over work of breathing Improve compliance of chest wall/abdomen: temporary while address IACS Cisatracurium (Nimbex) preferred: no renal or hepatic clearance 10

11 Steroids for ARDS Solumedrol 1mg/kg/Day (initial dose can be split Q12 or Q8) Slow taper over 1 month: Meduri Protocol Reduced mortality Decreased time on MV and in ICU w/o increase risk infection Prevent progression of exudative phase to proliferative/fibrotic phase Needs to be started <14 d Extracorporeal Therapies: ECMO 1 st used in adults 1972 VA for pulmonary & cardiac support VV pulmonary: true lung rest to allow recovery Ultraprotective MV: not relying on lung for gas exchange CO2 removal low blood flow (<1L/min) = smaller access Oxygenation needs >60% CO (5-6L/min) = larger access 11

12 Overview ECMO does NOT fix anything but allows for Tx of disease Sometimes Time is the Tx Time at a Cost needed to make Dx and then Tx Allows for interventions that could not be done: Bronch, Whole-Lung Lavage Improvements in technology has made easier & safer 75% of Adult ECMO Pts have been in last 5 yrs: H1N1 ECMO Dual Heart-Lung bypass or only Lung Oxygenation and CO2 removal VV: True Lung Rest ARDS, air leak, Asthma/COPD, DAH VA: PE, Blunt Cardiac Injury, pneumonectomy, myocarditis, MI, Cardiac Arrest Different configurations for VV or VA Two Catheters vs Single dual-lumen catheter (VV only) 12

13 8/13/2018 VV: Pulmonary 47 y/o Flu: 25F Fem Outflow; 23F IJ Inflow 13

14 VA: Cardiac and Pulmonary 14

15 Indications VV: ARDS: PaO 2 /FiO 2 <80 mmhg despite optimization Murray Score: P/F, PEEP, compliance, CXR quadrants Hypercapnic respiratory failure: ph <7.20 VA: Refractory cardiogenic shock Cardiac arrest with chance of recovery Failure to wean from cardiopulmonary bypass As a bridge to cardiac transplantation or VAD V-V ECMO If Risk Death>Risk of ECMO it should be Considered 15

16 Contraindications If the cause is irreversible For respiratory failure, if on MV>10 D outcomes may be poor in this population May exclude: >70, morbid obesity, neurologic dysfunction, poor preexisting status VA: Anticoagulation is contraindicated: bleeding, TBI, ICH For cardiac failure, if VAD or transplant is contraindicated Outcomes The Conventional MV vs ECMO for Severe Acute Respiratory failure (CESAR) trial randomly assigned 180 patients with severe ARDS to a single ECMO center in the UK or continued conventional management ECMO had significantly increased survival without disability at six months: 63 vs 47% 85% percent of the patients referred to an ECMO center were managed with ECMO, while the others improved with advanced conventional ventilation and management 16

17 Newest ARDS Study NEJM 2018 Randomized Study 125 in each group: Control vs ECMO (earlier use than rescue) 11% mortality decrease in ECMO group BUT allowed Crossover of RESCUE ECMO for 35 pts in Control Group IF account for these pts then mortality decrease is 24% Still use conservative Tx unless Pt in extremis or clearly will reach that point soon 21 y/o man MVC: L SQ air 17

18 Thoracotomy x2: 6.88/97/49 23F Drain and 21F Return 18

19 Hospital Course 7.44/45/67 Ventilation easier to achieve than Oxygenation No heparin for >48 hrs as L Chest STILL OPEN Closed at bedside s/p packs removed PO2 steadily improved and APRV weaned Drop & Stretch REST SETTINGS 35% FiO2 Coughing and suctioning old blood from lung injury CXR improving daily Day 5: decannulated day 6 19

20 Permissive Hypoxemia Sat <88% DO2 = CO x 1.34 Hgb x Sat x PO2 Delivery is 4x HIGHER than tissue consumption at rest Can tolerate low Sat ~80% IF CO/CI and Hgb are OPTIMAL May need to lower O2 consumption: hypothermia, sedation, paralytics(?) Verify adequate tissue oxygenation: Lactate, Venous Sat, UO, CNS exam Case #2: 26 yo man s/p OD 20

21 Time Course 7.22/58/49 on 100% (5am on arrival) Bronchoscopy vomitus in airways 7.29/50/45 (7am 2 hr later) Sedation/paralytics OFF. PRVC changed to APRV 7.30/48/66 (10am 3 hr later) Pressors OFF and Pt awake writing notes 7.39/45/89 on 70% (8 hr later) so P/F 127 No Longer SEVERE ARDS 7.46/47/122 on 40% (2 d later) so P/F >300 No Longer Qualifies for ARDS Accept Less than Optimal numbers to prevent VILI and allow lung recovery 5 days s/p Adm 21

22 ED Management Guide Volume or Pressure Control mode: 6cc/kg Ideal wt. Plateau P <30 PEEP titrate for goal: Oxygenation (Sat, P/F) and Recruitment (CT, US, Vol/Pres) Optimize Position: upright, decub, prone Consider Inhaled Flolan Consider IV Steroids Trial APRV (if comfort level) vs Paralytic Consult or Transfer for ECMO Questions and Comments Thank You for Your Attention 22

23 References Thiagarajan RR, Brogan TV, Scheurer MA, et al. Extracorporeal membrane oxygenation to support cardiopulmonary resuscitation in adults. Ann Thorac Surg. 2009; 87(3): ECMO registry of Extracorporeal Life Support Organization. Available at Accessed March 9th, Brogan TV, Thiagarajan RR, Rycus PT, et al. Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multi-center database. Intensive Care Med. 2009; 35(12): Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009; 374(9698): Davies A, Jones D, Bailey M, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA. 2009; 302(17):